Vitrasert en es it fr

Categoria

Vitrasert Nombres de marca, Vitrasert Analogos

Vitrasert Marca los nombres de mezcla

  • No information avaliable
  • Vitrasert Formula quimica

    C9H13N5O4

    Vitrasert RX enlace

    http://www.rxlist.com/cgi/generic2/vitrasert.htm

    Vitrasert FDA hoja

    Vitrasert FDA

    Vitrasert MSDS (hoja de seguridad de materiales)

    Vitrasert MSDS

    Vitrasert Sintesis de referencia

    Alhede, Boerge, et al;. J. Org;. 56, 6, 2139 a 2143 (1991)

    Vitrasert Peso molecular

    255.231 g/mol

    Vitrasert Punto de fusion

    250 oC

    Vitrasert H2O Solubilidad

    Vitrasert Estado

    Solid

    Vitrasert LogP

    -1.438

    Vitrasert Formas de dosificacion

    Oculares insertar, Cápsula oral, por inyección

    Vitrasert Indicacion

    Para la inducción y mantenimiento en el tratamiento de la infección por citomegalovirus (CMV) en pacientes inmunocomprometidos, incluyendo pacientes con síndrome de inmunodeficiencia adquirida (SIDA). También se utiliza en el tratamiento

    Vitrasert Farmacologia

    El ganciclovir es un nucleósido análogo sintético de la 2'-desoxiguanosina, que inhibe la replicación del virus del herpes tanto in vitro como in vivo. Sensibles a los virus humanos incluyen el citomegalovirus (CMV), herpes simplex virus 1 y 2 (HSV-1, HSV-2), virus de Epstein-Barr (EBV) y el virus varicela-zóster (VVZ), sin embargo los estudios clínicos se han limitado a la evaluación de la eficacia en pacientes con infección por CMV. Ganciclovir la maquinaria viral necesaria para transmitir el virus a otras células.

    Vitrasert Absorcion

    Vitrasert Toxicidad

    Oral, DL50:> 2g/kg. Por vía intravenosa, el perro LD50: 150mg/kg>. Los síntomas de sobredosis incluyen pancitopenia irreversible, empeoramiento de los síntomas GI, e insuficiencia renal aguda. Agente de sospecha de cáncer.

    Vitrasert Informacion de Pacientes

    All patients should be informed that the major toxicities of ganciclovir are granulocytopenia
    (neutropenia), anemia and thrombocytopenia and that dose modifications may be required, including
    discontinuation. The importance of close monitoring of blood counts while on therapy should be emphasized.
    Patients should be informed that ganciclovir has been associated with elevations in serum creatinine.

    Patients should be instructed to take CYTOVENE capsules with food to maximize bioavailability.

    Patients should be advised that ganciclovir has caused decreased sperm production in animals and may cause
    infertility in humans. Women of childbearing potential should be advised that ganciclovir causes birth
    defects in animals and should not be used during pregnancy. Women of childbearing potential should be
    advised to use effective contraception during treatment with CYTOVENE-IV or CYTOVENE. Similarly, men
    should be advised to practice barrier contraception during and for at least 90 days following treatment
    with CYTOVENE-IV or CYTOVENE.

    Patients should be advised that ganciclovir causes tumors in animals. Although there is no information
    from human studies, ganciclovir should be considered a potential carcinogen.

    All HIV+ Patients: These patients may be receiving zidovudine (Retrovir?*). Patients should be counseled
    that treatment with both ganciclovir and zidovudine simultaneously may not be tolerated by some patients
    and may result in severe granulocytopenia (neutropenia). Patients with AIDS may be receiving didanosine
    (Videx?#). Patients should be counseled that concomitant treatment with both ganciclovir and didanosine
    can cause didanosine serum concentrations to be significantly increased.

    HIV+ Patients With CMV Retinitis: Ganciclovir is not a cure for CMV retinitis, and immunocompromised
    patients may continue to experience progression of retinitis during or following treatment. Patients
    should be advised to have ophthalmologic follow-up examinations at a minimum of every 4 to 6 weeks while
    being treated with CYTOVENE-IV or CYTOVENE. Some patients will require more frequent follow-up.

    Transplant Recipients: Transplant recipients should be counseled regarding the high frequency of impaired
    renal function in transplant recipients who received CYTOVENE-IV solution in controlled clinical trials,
    particularly in patients receiving concomitant administration of nephrotoxic agents such as cyclosporine
    and amphotericin B. Although the specific mechanism of this toxicity, which in most cases was reversible,
    has not been determined, the higher rate of renal impairment in patients receiving CYTOVENE-IV solution
    compared with those who received placebo in the same trials may indicate that CYTOVENE-IV played a
    significant role.

    Vitrasert Organismos afectados

    El herpes virus humano